The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
Immune checkpoint inhibitors (ICIs) and immunotherapy have proven to be a transformative therapy for many forms of cancer treatment. While many antibodies targeting the PD-1, PD-L1, and CTLA-4 pathways have been approved for clinical use by the FDA, it is clear that a single ICI is not sufficient to eradicate disease. ICI combination strategies are being extensively investigated to advance cancer treatment to next curative stage. Among the immune checkpoint inhibitors being actively investigated, the potential of VISTA (V-domain Ig suppressor of T cell activation), a unique B7 family member that functions as both ligand and receptor, is being actively pursued. This article summarizes the expression and immunomodulatory effects of VISTA in autoimmune diseases and cancer, and assesses its potential as an additional component of immune checkpoint cancer therapy.
['Wang|Geng|G|', 'Tai|Risheng|R|', 'Wu|Yanshuang|Y|', 'Yang|Shanru|S|', 'Wang|Jingjing|J|', 'Yu|Xiaolan|X|', 'Lei|Lei|L|', 'Shan|Zhiyan|Z|', 'Li|Na|N|']
D000818:Animals D001327:Autoimmune Diseases D060887:B7 Antigens D005786:Gene Expression Regulation D006801:Humans D056747:Immunomodulation D008213:Lymphocyte Activation D051379:Mice D009369:Neoplasms
VISTA Autoimmune diseases Immune checkpoint inhibitor Cancer immunotherapy Combination therapy